Med BioGene Inc.

Med BioGene Inc.

December 03, 2009 08:30 ET

Med BioGene Announces Poster Presentations of LungExpress Dx Validation Study and Health Economics Evaluation at AACR-IASLC Meeting in January

VANCOUVER, BRITISH COLUMBIA--(Marketwire - Dec. 3, 2009) - Med BioGene Inc. (TSX VENTURE:MBI) today announced that two poster presentations in respect of LungExpress Dx™ will be made at the January meeting of the American Association for Cancer Research - International Association for the Study of Lung Cancer Joint Conference on Molecular Origins of Lung Cancer: Prospects for Personalized Prevention and Therapy (

The first presentation will be made by MBI and details the initial results of a health economic evaluation of LungExpress Dx. The study was undertaken my MBI and Quorum Consulting of San Francisco and outlines the potential clinical utility and cost savings associated with the use of LungExpress Dx in the management of early-stage non-small-cell lung cancer (NSCLC) patients.

The second presentation will be made by MBI's collaborators at the University Health Network (Princess Margaret Hospital) in Toronto and details the positive results from the previously announced validation study of LungExpress Dx. The study met its primary endpoint in confirming that the 15-gene expression-based signature underlying LungExpress Dx is an independent prognostic marker in early-stage NSCLC for identifying, more selectively than routine staging, patients with significantly different prognoses and may provide additional clinical value beyond standard measures of risk.

The meeting is being held in Coronado, California at the Loews Coronado Bay Resort and Spa. The presentations will be made at poster sessions as follows:

Date Time Title of Abstract Location
---------------- ------------ -------------------------- ----------------

Tuesday, 12:30 p.m. Initial evaluation of Poster Session A
January 12, 2010 to 2:30 p.m. the health economic
impact of a prognostic
15-gene expression-based
signature in early-stage
NSCLC patient management

Wednesday, 4:30 p.m. Validation of a prognostic Poster Session B
January 13, 2010 to 6:30 p.m. gene signature for early-
stage NSCLC in an
independent cohort

About Med BioGene

MBI is a life science company focused on the development and commercialization of genomic-based personalized clinical laboratory diagnostic tests. MBI is committed to advancing personalized medicine by commercializing tests that provide clinically relevant information to improve patient treatment and reduce health care costs. For more information, please visit

Certain statements in this press release contain forward-looking information and statements ("forward-looking statements") under applicable Canadian and United States securities legislation. Words such as "anticipates," "believes," "estimates," "expects," "intends," "may," "plans," "projects," "will," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward looking statements include, but are not limited to, that with respect to future profits, future product revenues, future operations and plans, the use of proceeds from financings, the timing of clinical trials and the completion date for clinical trials and the prospects for negotiating partnerships or collaborations and their timing. These forward-looking statements are only a prediction based upon MBI's current expectations, and actual events or results may differ materially. MBI may not actually achieve the plans, intentions or expectations disclosed in its forward-looking statements. Forward-looking statements are subject to known and unknown risks and uncertainties and are based on uncertain assumptions that could cause MBI's actual results and the timing of events to differ materially from those anticipated in such forward-looking information. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. MBI's forward-looking statements do not reflect the potential impact of any future partnerships, collaborations, acquisitions, mergers, dispositions, joint ventures or investments that MBI may make. All forward-looking statements are qualified in their entirety by this cautionary statement and MBI undertakes no obligation to revise or update any forward-looking statements as a result of new information, future events or otherwise after the date of this press release, other than as required by applicable law.

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.

Contact Information